Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

Inclusion Criteria: * Willing and able to provide written informed consent * History of histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology * Patients with metastatic castration-sensitive (CSPC) or castration-resistant prostate cancer (CRPC) with evidence of metastatic disease on conventional imaging with CT or bone scan. * Prior docetaxel-based chemotherapy is permitted * Documented metastatic prostate cancer progression as assessed by the treating oncologist with either one or both of the following and has not initiated a new therapy after determination of progression: Rising PSA over a minimum 1-week interval and/or radiographic progression in soft tissue and bone metastases (combination of bony and soft tissue metastases) * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 Exclusion Criteria: * Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection * Administered a radioisotope ≤5 physical half-lives prior to the date of study PET/CT * Administered IV X-ray contrast medium ≤24 hours prior to the date of study PET/CT * Administered oral contrast medium ≤120 hours prior to the date of study PET/CT * Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study